Aller au contenu principal
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Observationnelle500 participants recherchés21 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Affections

  • Limbal Stem Cell Deficiency

Éligibilité

Éligibilité
SexeTous
Âges12 Years – 99 Years
Volontaires sainsNon
Méthode d'échantillonnagePROBABILITY_SAMPLE

Population de l'étude

Adult and adolescent subjects with qualifying LSCD

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeObservationnelle
PhaseNon précisé dans la fiche du registre
RépartitionNon précisé dans la fiche du registre
Modèle d'interventionNon précisé dans la fiche du registre
Objectif principalNon précisé dans la fiche du registre
InsuNon précisé dans la fiche du registre
Recrutement500 participants recherchés

Promoteur et collaborateurs

  • Claris Biotherapeutics, Inc. Promoteur

Groupes et interventions

  • Non-interventional

    No product administration.

Interventions

  • Autre Non-interventional

    Non-interventional

Critères de jugement

  1. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Délai Screening through Week 84

  2. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Délai Screening through Week 84

  3. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Délai Screening through Week 84

  4. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Délai Screening through Week 84

  5. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Délai Screening through Week 84

  6. Critère de jugement principal

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Délai Screening through Week 84

  7. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Délai Screening through Week 84

  8. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Délai Screening through Week 84

  9. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Délai Screening through Week 84

  10. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Délai Screening through Week 84

  11. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Délai Screening through Week 84

  12. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Délai Screening through Week 84

  13. Critère de jugement secondaire

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Délai Screening through Week 84

Dates

Dates
Date de début22 mai 2026 (réelle)
Achèvement principal1 mars 2028 (estimée)
Achèvement1 mars 2028 (estimée)
Première publication9 juin 2026 (réelle)
Dernière mise à jour18 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

21 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Claris Investigative SiteCarmelIndianaEn recrutement
Claris Investigative SiteCranberry TownshipPennsylvaniaEn recrutement
Claris Investigative SiteDraperUtahEn recrutement
Claris Investigative SiteHuntington BeachCaliforniaEn recrutement
Claris Investigative SiteIndianapolisIndianaEn recrutement
Claris Investigative SiteKansas CityMissouriEn recrutement
Claris Investigative SiteLa JollaCaliforniaEn recrutement
Claris Investigative SiteLos AngelesCaliforniaEn recrutement
Claris Investigative SiteLouisvilleKentuckyEn recrutement
Claris Investigative SiteMinnetonkaMinnesotaEn recrutement
Claris Investigative SiteNorfolkVirginiaEn recrutement
Claris Investigative SiteOverland ParkKansasEn recrutement
Claris Investigative SitePalisades ParkNew JerseyEn recrutement
Claris Investigative SitePortlandOregonEn recrutement
Claris Investigative SiteRockville CentreNew YorkEn recrutement
Claris Investigative SiteSan AntonioTexasEn recrutement
Claris Investigative SiteSioux FallsSouth DakotaEn recrutement
Claris Investigative SiteSmyrnaTennesseeEn recrutement
Claris Investigative SiteSouth DartmouthMassachusettsEn recrutement
Claris Investigative SiteTampaFloridaEn recrutement
Claris Investigative SiteWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 18 novembre 2026

    Site ajouté

    13 sites added (21 total)

    821

  2. 6 août 2026

    Site ajouté

    6 sites added (8 total)

    28